MedTrace Logo

Topotecan and Cisplatin Versus Etoposide and Carboplatin in 1st Line Treatment of Patients With Small Cell Lung Cancer and Extensive Disease (SCLC-ED)

NCT00812266 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 281

Last updated 2016-01-26

No results posted yet for this study

Summary

Randomised trial comparing standard chemotherapy with carboplatin and etoposide with a combination of topotecan and cisplatin in patients with inoperable lung cancer of small cell type.

Conditions

Interventions

DRUG

topotecan + cisplatin

topotecan IV 2 mg/sqm d1-3 + cisplatin IV 50 mg/sqm d3 q3W

DRUG

Etoposide + carboplatin

Etoposide 120 mg/sqm IV d 1-3 + carboplatin AUC 5 d1 q3W

Sponsors & Collaborators

  • Danish Oncological Lung Cancer Group

    lead OTHER

Principal Investigators

  • Seppo W Langer, MD PhD · Dept. of Oncology, Rigshospitalet, Copenhagen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2013-12-31
Completion
2015-01-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00812266 on ClinicalTrials.gov